GRAIL, LLC (GRAL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
GRAIL, LLC stock (GRAL) is currently trading at $52.29. GRAIL, LLC PS ratio (Price-to-Sales) is 13.56. Analyst consensus price target for GRAL is $83.40. WallStSmart rates GRAL as Sell.
- GRAL PE ratio analysis and historical PE chart
- GRAL PS ratio (Price-to-Sales) history and trend
- GRAL intrinsic value — DCF, Graham Number, EPV models
- GRAL stock price prediction 2025 2026 2027 2028 2029 2030
- GRAL fair value vs current price
- GRAL insider transactions and insider buying
- Is GRAL undervalued or overvalued?
- GRAIL, LLC financial analysis — revenue, earnings, cash flow
- GRAL Piotroski F-Score and Altman Z-Score
- GRAL analyst price target and Smart Rating
GRAIL, LLC
📊 No data available
Try selecting a different time range
Smart Analysis
GRAIL, LLC (GRAL) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
GRAIL, LLC (GRAL) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
74.30% of shares held by major funds and institutions
GRAIL, LLC (GRAL) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 13.6x annual revenue
Small-cap company with higher risk but more growth potential
Solid revenue growth at 14.00% per year
Supporting Valuation Data
GRAIL, LLC (GRAL) Detailed Analysis Report
Overall Assessment
This company scores 32/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.74) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (13.56) suggest expensive pricing. Growth concerns include Revenue Growth at 14.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -16.10%, Operating Margin at -285.40%, Profit Margin at -277.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -16.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 14.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GRAL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GRAL's Price-to-Sales ratio of 13.56x sits near its historical average of 13.43x (43th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 8% below its historical high of 14.81x set in Mar 2026, and 12% above its historical low of 12.15x in Mar 2026.
Compare GRAL with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for GRAIL, LLC (GRAL) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
GRAIL, LLC is in a turnaround phase, with management focused on restoring profitability. Revenue reached 147M with 14% growth year-over-year. The company is currently unprofitable, posting a -277.5% profit margin.
Key Findings
Spending 32% of revenue (47M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -277.5% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -65M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact GRAIL, LLC.
Bottom Line
GRAIL, LLC is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About GRAIL, LLC(GRAL)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
GRAIL, LLC is a pioneering biotechnology firm focused on revolutionizing cancer detection through its state-of-the-art blood tests designed for early diagnosis. With its proprietary genomic technologies, GRAIL is at the forefront of the multi-cancer early detection (MCED) market, empowering individuals with essential information for proactive healthcare management. The company's dedication to advancing precision medicine not only aims to improve patient outcomes but also addresses critical gaps in cancer screening and diagnostics, positioning GRAIL as a crucial player in the future landscape of oncology.